Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

Altimmune (ALT) Return on Capital Employed: 2011-2025

Historic Return on Capital Employed for Altimmune (ALT) over the last 13 years, with Sep 2025 value amounting to -0.47%.

  • Altimmune's Return on Capital Employed rose 26.00% to -0.47% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.47%, marking a year-over-year increase of 26.00%. This contributed to the annual value of -0.63% for FY2024, which is 14.00% down from last year.
  • As of Q3 2025, Altimmune's Return on Capital Employed stood at -0.47%, which was up 17.74% from -0.57% recorded in Q2 2025.
  • In the past 5 years, Altimmune's Return on Capital Employed registered a high of -0.25% during Q1 2021, and its lowest value of -0.78% during Q4 2024.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.54% (2023), whereas its average is -0.59%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first grew by 30bps in 2021, then declined by 27bps in 2022.
  • Altimmune's Return on Capital Employed (Quarterly) stood at -0.46% in 2021, then climbed by 2bps to -0.44% in 2022, then dropped by 10bps to -0.54% in 2023, then fell by 23bps to -0.78% in 2024, then increased by 26bps to -0.47% in 2025.
  • Its Return on Capital Employed stands at -0.47% for Q3 2025, versus -0.57% for Q2 2025 and -0.71% for Q1 2025.